IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v21y2023i4d10.1007_s40258-023-00803-x.html
   My bibliography  Save this article

A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany

Author

Listed:
  • Afschin Gandjour

    (Frankfurt School of Finance and Management)

Abstract

Purpose Value-based pricing of new, innovative health technologies defined as pricing through economic evaluation requires the use of a basic cost-effectiveness threshold. This study presents a cost-effectiveness model that determines the cost-effectiveness threshold for life-extending new, innovative technologies based on health system opportunity costs. Methods To estimate health system opportunity costs, the study used German data and examined the period between 1896 and 2014. To this end, it determined intertemporal differences in the remaining lifetime spending and life expectancy by age and gender. To account for the age composition of the population, it weighted age-specific intertemporal changes in the remaining lifetime spending and life expectancy by the age-specific population size. To estimate life expectancy gains solely attributable to the health care system, it used aggregated data on amenable mortality. It calculated the cost-effectiveness ratio of health care spending in the German health care system on average and at the margin. Results Based on the cost-effectiveness ratio of health care spending at the margin, the threshold value for life-prolonging new, innovative technologies was at least €42,634 per life-year gained, with a point estimate of €88,107 per life-year gained. Based on the average ratio, the threshold value dropped below €34,000 per life-year gained. Conclusion This study provides new evidence on the cost-effectiveness threshold for value-based pricing of new, innovative technologies. Data from Germany suggest that a threshold value based on health care spending at the margin is considerably higher than that based on the average ratio.

Suggested Citation

  • Afschin Gandjour, 2023. "A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany," Applied Health Economics and Health Policy, Springer, vol. 21(4), pages 627-635, July.
    • Handle: RePEc:spr:aphecp:v:21:y:2023:i:4:d:10.1007_s40258-023-00803-x
    DOI: 10.1007/s40258-023-00803-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40258-023-00803-x
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40258-023-00803-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Birch, Stephen & Gafni, Amiram, 2015. "On the margins of health economics: a response to ‘resolving NICE’S nasty dilemma’," Health Economics, Policy and Law, Cambridge University Press, vol. 10(2), pages 183-193, April.
    2. Nolte, Ellen & Scholz, Rembrandt & Shkolnikov, Vladimir & McKee, Martin, 2002. "The contribution of medical care to changing life expectancy in Germany and Poland," Social Science & Medicine, Elsevier, vol. 55(11), pages 1905-1921, December.
    3. Valérie Paris & Annalisa Belloni, 2013. "Value in Pharmaceutical Pricing," OECD Health Working Papers 63, OECD Publishing.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
    2. Melanie Büssgen & Tom Stargardt, 2023. "10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?," Applied Health Economics and Health Policy, Springer, vol. 21(5), pages 751-759, September.
    3. Haan, Peter & Prowse, Victoria, 2014. "Longevity, life-cycle behavior and pension reform," Journal of Econometrics, Elsevier, vol. 178(P3), pages 582-601.
    4. Sabine Vogler & Valérie Paris & Alessandra Ferrario & Veronika J. Wirtz & Kees Joncheere & Peter Schneider & Hanne Bak Pedersen & Guillaume Dedet & Zaheer-Ud-Din Babar, 2017. "How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 307-321, June.
    5. Jinwook Bahk & Kyunghee Jung-Choi, 2020. "The Contribution of Avoidable Mortality to the Life Expectancy Gains in Korea between 1998 and 2017," IJERPH, MDPI, vol. 17(18), pages 1-10, September.
    6. Eun, Sang Jun, 2019. "Avoidable, amenable, and preventable mortalities in South Korea, 2000–2017: Age-period-cohort trends and impact on life expectancy at birth," Social Science & Medicine, Elsevier, vol. 237(C), pages 1-1.
    7. Adriana Castelli & Olena Nizalova, 2011. "Avoidable mortality: what it means and how it is measured," Working Papers 063cherp, Centre for Health Economics, University of York.
    8. William C. N. Dunlop & C. Daniel Mullins & Olaf Pirk & Ron Goeree & Maarten J. Postma & Ashley Enstone & Louise Heron, 2016. "BEACON: A Summary Framework to Overcome Potential Reimbursement Hurdles," PharmacoEconomics, Springer, vol. 34(10), pages 1051-1065, October.
    9. Sun-Hong Kwon & Hea-Sun Park & Young-Jin Na & Chul Park & Ju-Young Shin & Hye-Lin Kim, 2021. "Price Reduction of Anticancer Drugs from 2007 to 2019 in South Korea: The Impact of Pharmaceutical Cost-Containment Policies," Applied Health Economics and Health Policy, Springer, vol. 19(3), pages 439-450, May.
    10. Vogt, Tobias C. & Kluge, Fanny A., 2015. "Can public spending reduce mortality disparities? Findings from East Germany after reunification," The Journal of the Economics of Ageing, Elsevier, vol. 5(C), pages 7-13.
    11. Simona-Andreea Apostu & Valentina Vasile & Valentin Sava, 2021. "Do Cardiovascular Diseases Significantly Influence Healthy Aging?," IJERPH, MDPI, vol. 18(14), pages 1-15, July.
    12. Rotar, Alexandru M. & Preda, Alin & Löblová, Olga & Benkovic, Vanesa & Zawodnik, Szymon & Gulacsi, Laszlo & Niewada, Maciej & Boncz, Imre & Petrova, Guenka & Dimitrova, Maria & Klazinga, Niek, 2018. "Rationalizing the introduction and use of pharmaceutical products: The role of managed entry agreements in Central and Eastern European countries," Health Policy, Elsevier, vol. 122(3), pages 230-236.
    13. Magdalena Muszyñska & Roland Rau Roland, 2014. "Did Men Benefit More from Medical Progress in Recent Decades? Cause-of-Death Contributions to the Decreasing Sex-Gap in Life Expectancy in the United States," Working Papers 72, Institute of Statistics and Demography, Warsaw School of Economics.
    14. Michael Mühlichen, 2019. "Avoidable Mortality in the German Baltic Sea Region Since Reunification: Convergence or Persistent Disparities?," European Journal of Population, Springer;European Association for Population Studies, vol. 35(3), pages 609-637, July.
    15. Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
    16. Claude Montmarquette & Stéphanie Boulenger & Joanne Castonguay, 2014. "Les risques liés à la création de PHARMA-QUEBEC," CIRANO Project Reports 2014rp-05, CIRANO.
    17. Mühlichen, Michael & Lerch, Mathias & Sauerberg, Markus & Grigoriev, Pavel, 2023. "Different health systems – Different mortality outcomes? Regional disparities in avoidable mortality across German-speaking Europe, 1992–2019," Social Science & Medicine, Elsevier, vol. 329(C).
    18. Pavel Grigoriev & Markéta Pechholdová, 2017. "Health Convergence Between East and West Germany as Reflected in Long-Term Cause-Specific Mortality Trends: To What Extent was it Due to Reunification?," European Journal of Population, Springer;European Association for Population Studies, vol. 33(5), pages 701-731, December.
    19. Anna Sagan & Marina Karanikolos & Małgorzata Gałązka-Sobotka & Martin McKee & Monika Rozkrut & Iwona Kowalska-Bobko, 2022. "The Devil Is in the Data: Can Regional Variation in Amenable Mortality Help to Understand Changes in Health System Performance in Poland?," IJERPH, MDPI, vol. 19(7), pages 1-11, March.
    20. Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:21:y:2023:i:4:d:10.1007_s40258-023-00803-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.